tirzepatide vs semaglutide risks 2026: 22% vs 15% Weight Loss Guide Semaglutide vs Tirzepatide Side Effects:

No differences were observed in systolic blood pressure (SBP) or medical therapy for HF, except that patients with lower obesity class were more likely to be treated with sodium-glucose co-transporter-2 (SGLT2) inhibitors, and patients with higher obesity class were more likely to receive loop diuretics at higher dose

As you learn about our clients stories, please understand that recovery results vary

Fernstrm, M., Fernberg, U

By working collaboratively across the ecosystem, we help ensure that consumers have access to safe and effective solutions and medications. The End of the GLP-1 Shortage In October 2024, the FDA announced that the shortage of tirzepatide, the active ingredient in Mounjaro and Zepbound, was resolved, and shortages of other GLP-1s are also poised to be resolved in the near future